{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T02:36:10Z","timestamp":1780972570833,"version":"3.54.1"},"reference-count":149,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T00:00:00Z","timestamp":1384992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.jhep.2013.11.013","type":"journal-article","created":{"date-parts":[[2013,11,24]],"date-time":"2013-11-24T14:46:32Z","timestamp":1385304392000},"page":"872-884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting"],"prefix":"10.1016","volume":"60","author":[{"given":"Sarah","family":"Tischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2013.11.013_b0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-200544030-00005","article-title":"Mechanism-based inhibition of cytochrome P450 3A4 therapeutic drugs","volume":"44","author":"Zhou","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jhep.2013.11.013_b0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/1389200043335450","article-title":"Therapeutic drugs that behave as mechanism-based inhibitor of cytochrome P450 3A4","volume":"5","author":"Zhou","year":"2004","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.jhep.2013.11.013_b0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archinte.162.4.405","article-title":"Implications of cytochrome P540 interactions when prescribing medications for hypertension","volume":"1","author":"Flockart","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jhep.2013.11.013_b0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijpharm.2013.05.033","article-title":"From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation","volume":"452","author":"Knops","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jhep.2013.11.013_b0025","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-6143.2005.00748.x","article-title":"Pharmacokinetic principles of immunosuppressive drugs","volume":"5","author":"Srinivas","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2013.11.013_b0030","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/01.tp.0000188118.34633.bf","article-title":"Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation","volume":"81","author":"Yu","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2013.11.013_b0035","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1592\/phco.26.12.1730","article-title":"Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants","volume":"26","author":"Saad","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jhep.2013.11.013_b0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/0091270003261078","article-title":"Effects of St. John\u2019s wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers","volume":"44","author":"Herbert","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2013.11.013_b0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cld.2012.09.013","article-title":"Management of the transplant recipient with hepatitis C","volume":"17","author":"Burton","year":"2013","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2013.11.013_b0050","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/gast.1996.v110.pm8536853","article-title":"A longitudinal analysis of hepatitis C virus replication following liver transplantation","volume":"110","author":"Gane","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.11.013_b0055","first-page":"674","article-title":"HCV related fibrosis progression following liver transplantation: increase in recent years","volume":"32","author":"Berenguer","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2036.2010.04505.x","article-title":"Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation","volume":"33","author":"Guillouche","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2013.11.013_b0065","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2011.12.031","article-title":"Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy","volume":"56","author":"Berenguer","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0070","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/lt.21121","article-title":"Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence","volume":"13","author":"Sharma","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.11.013_b0075","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1053\/j.gastro.2012.01.030","article-title":"Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated Interferon","volume":"142","author":"Levitsky","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.11.013_b0080","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jhep.2010.11.012","article-title":"Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients","volume":"55","author":"Selzner","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0085","doi-asserted-by":"crossref","DOI":"10.1007\/s12072-013-9436-1","article-title":"Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival","author":"Sharma","year":"2013","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2013.11.013_b0090","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jhep.2006.10.017","article-title":"Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation","volume":"46","author":"Picciotto","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-6143.2008.02362.x","article-title":"Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent HCV infection","volume":"8","author":"Veldt","year":"2008","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2013.11.013_b0100","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.11.013_b0105","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.11.013_b0110","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0115","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.11.013_b0120","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.11.013_b0125","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.11.013_b0130","unstructured":"Boceprevir [package insert]. Whitehouse Station, NJ: Merck Laboratories; 2013."},{"key":"10.1016\/j.jhep.2013.11.013_b0135","unstructured":"Telaprevir [package insert]. Boston, MA: Vertex Pharmaceuticals; 2011."},{"key":"10.1016\/j.jhep.2013.11.013_b0140","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2012.07.035","article-title":"New therapies against HCV: expected risks and challenges associated with their use in the liver transplant setting","volume":"57","author":"McCaughan","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1665-2681(19)31022-1","article-title":"A review of drug interaction with boceprevir and telaprevir: implications for HIV and transplant patients","volume":"11","author":"Wilby","year":"2012","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0150","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/hep.25653","article-title":"Review and management of drug interaction with boceprevir and telaprevir","volume":"55","author":"Kiser","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0155","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2012.10.027","article-title":"Clinical management of drug-drug interactions in HCV therapy: challenges and solutions","volume":"58","author":"Burger","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0160","doi-asserted-by":"crossref","DOI":"10.1038\/nrgastro.2013.106","article-title":"Drug-drug interactions during antiviral therapy for chronic hepatitis C","author":"Kiser","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0165","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1128\/AAC.00653-11","article-title":"Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin","volume":"55","author":"Lee","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2013.11.013_b0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/cld.10","article-title":"Managing drug-drug interactions with boceprevir and telaprevir","volume":"1","author":"Rangnekar","year":"2012","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2013.11.013_b0175","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1128\/AAC.02347-12","article-title":"Pharmacokinetic evaluation of the interaction between the hepatitis C virus protease inhibitor boceprevir and the 3-hydroxy-3-methylguaryl coenzyme a reductase inhibitors atorvastatin and pravastatin","volume":"57","author":"Huloskotte","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2013.11.013_b0180","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1177\/0091270011419850","article-title":"Effect of telaprevir on the pharmacokinetics of midazolam and digoxin","volume":"52","author":"Garg","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2013.11.013_b0185","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1177\/0091270011419855","article-title":"The pharmacokinetic interaction between oral contraceptives containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir","volume":"52","author":"Garg","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2013.11.013_b0190","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/hep.26612","article-title":"Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation","volume":"58","author":"Reddy","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0195","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/hep.25831","article-title":"Pharmacokinetic interaction between the hepatitis C virus and protease inhibitor boceprevir and cyclosporine and tacrolimus in health volunteers","volume":"56","author":"Hulskotte","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0200","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.24443","article-title":"Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus","volume":"54","author":"Garg","year":"2011","journal-title":"Heptology"},{"key":"10.1016\/j.jhep.2013.11.013_b0205","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/S0168-8278(13)60465-1","article-title":"Pharmacokinetics interactions between the HCV protease inhibitor boceprevir and sirolimus in healthy subject","volume":"S58","author":"Hulskotte","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0210","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1128\/AAC.01151-12","article-title":"Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence","volume":"56","author":"Coilly","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2013.11.013_b0215","first-page":"#1736","article-title":"Twice daily telaprevir in combination with peginterferon alfa-2a\/ribavirin in genotype 1 HCV liver transplant recipients: interim Week 16 Calcineurin inhibitor, telaprevir, and ribavirin pharmacokinetics from the prospective, multicenter, REFRESH study","volume":"53","author":"Fontana","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0220","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/lt.23623","article-title":"Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients","volume":"19","author":"O\u2019Leary","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.11.013_b0225","first-page":"1076A","article-title":"Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and prednisone in healthy volunteers","volume":"56","author":"Jumes","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0230","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/lt.23669","article-title":"Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation","volume":"19","author":"Pungpapong","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.11.013_b0235","article-title":"Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience","author":"Coily","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0240","first-page":"#3","article-title":"Twice daily telaprevir in combination with peginterferon alfa-2a\/ribavirin in genotype 1 HCV liver transplant recipients: interim Week 16 Safety and Efficacy results of the Prospective, Multicenter REFRESH Study","volume":"58","author":"Brown","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0245","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/lt.23542","article-title":"Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data","volume":"18","author":"Werner","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.11.013_b0250","first-page":"1369","article-title":"Post liver transplant therapy with telaprevir for recurrent hepatitis C","volume":"12","author":"De Oliverira Pereira","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2013.11.013_b0255","first-page":"LB01","article-title":"Initial experience with telaprevir for treating hepatitis C virus in liver transplant recipients: virologic response, safety and tolerability","volume":"12","author":"Burton","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2013.11.013_b0260","first-page":"32","article-title":"A high rate of eRVR with protease inhibitor-triple HCV therapy in liver transplant recipients: a multicenter study from CRUSH-C","volume":"S5","author":"O\u2019Leary","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2013.11.013_b0265","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/lt.23496","article-title":"Rapid recovery of cytochrome P450 3A4 after protease inhibitor withdrawal in post-liver transplant patients","volume":"18","author":"Oo","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.11.013_b0270","first-page":"368","article-title":"Protease inhibitor therapy post-liver transplantation in the treatment of hepatitis c virus infection","volume":"9","author":"Nair","year":"2013","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0275","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/liv.12062","article-title":"Current management and perspectives for HCV recurrent after liver transplantation","volume":"33","author":"Coilly","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2013.11.013_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(13)60874-0","article-title":"Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir","author":"Mauss","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0285","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.bcp.2012.07.032","article-title":"Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters","volume":"84","author":"Kunze","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jhep.2013.11.013_b0290","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1034\/j.1600-0676.2001.021004260.x","article-title":"Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C","volume":"21","author":"Herold","year":"2001","journal-title":"Liver"},{"key":"10.1016\/j.jhep.2013.11.013_b0295","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.clpt.2006.05.006","article-title":"Liver disease selectively modulates cytochrome P450-mediated metabolism","volume":"80","author":"Frey","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2013.11.013_b0300","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1053\/jlts.2003.50233","article-title":"Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection","volume":"9","author":"Kugelmas","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.11.013_b0305","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"Poordad","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.11.013_b0310","first-page":"1515A","article-title":"A 12week interferon-free treatment regimen with ABT-450\/R, ABT-267, ABT-333, and ribavirin achieves SVR12 rates of 99% in treatment na\u00efve patients and 93% in prior null-responders with HCV genotype 1 infection","volume":"56","author":"Kowdley","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0315","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jhep.2012.10.019","article-title":"Perspectives and challenges of interferon-free therapy for chronic hepatitis C","volume":"58","author":"Lange","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0320","doi-asserted-by":"crossref","first-page":"S568","DOI":"10.1016\/S0168-8278(13)61412-9","article-title":"Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: results from QUEST-2 a phase III trial","volume":"58S","author":"Manns","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0325","doi-asserted-by":"crossref","first-page":"S574","DOI":"10.1016\/S0168-8278(13)61424-5","article-title":"Simeprevir (TMC435) with peginterferon\/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-na\u00efve patients: results from QUEST-1 a phase III trial","volume":"58S","author":"Jacobson","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0330","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/hep.26276","article-title":"Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype1 HCV: SILEN-C1 trial","volume":"57","author":"Sulkowski","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0335","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/hep.26386","article-title":"Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 Trial","volume":"57","author":"Sulkowski","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0340","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(13)60247-0","article-title":"Sofosbuvir with pegylated interferon alfa-2 a and ribavirin for treatment-na\u00efve patients with hepatitis C genotype 1 (ATOMIC): an open-label, randomized, multicenter phase 2 trial","volume":"381","author":"Kowdley","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2013.11.013_b0345","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1473-3099(12)70138-X","article-title":"Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomized, parallel-group, double-placebo, placebo-controlled, dose-finding, phase 2a trial","volume":"12","author":"Pol","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2013.11.013_b0350","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","article-title":"Once-daily simeprevir (TMC 435) with pegylated interferon and ribavirin in treatment-na\u00efve genotype I hepatitis C: the randomized PILLAR study","volume":"58","author":"Fried","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0355","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa1213557","article-title":"Faldaprevir and deleobuvir for HCV genotype 1 infection","volume":"369","author":"Zeuzem","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.11.013_b0360","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C Genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.11.013_b0365","first-page":"231A","article-title":"Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNRr), mericitabine (MCB), and ribavirin (R)\u00b1peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from MATTERHORN study","volume":"56","author":"Feld","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0370","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.11.013_b0375","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.11.013_b0380","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0168-8278(13)60066-5","article-title":"GS-5885 (Ledipasvir)+GS-9451+peginterferon and ribavirin for 6 or 12weeks achieves high SVR12 rates in treatment na\u00efve genotype 1 IL28B CC patients","volume":"58S","author":"Thompson","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0385","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2011.12.029","article-title":"A phase I, randomized, placebo controlled, 3-day dose -ranging study of GS-5885: an NS5A inhibitor, in patients with genotype 1 hepatitis C","volume":"57","author":"Lawitz","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0390","first-page":"213A","article-title":"No clinically significant interaction between the investigational HCV protease inhibitor, TMC435 and the immunosuppressives cyclosporine and tacrolimus","volume":"58","author":"Ouwerkerk-Mahadevan","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0395","first-page":"S478","article-title":"A 12week interferon-free treatment regimen with ABT-450\/R, ABT-267, ABT-333, and ribavirin achieves SVR12 rates of 99% in treatment na\u00efve patients and 93% in prior null-responders with HCV genotype 1 infection","volume":"56S","author":"Kowdley","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0400","doi-asserted-by":"crossref","first-page":"S488","DOI":"10.1016\/S0168-8278(11)61238-5","article-title":"Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3\/4A protease inhibitor, BI201335","volume":"54","author":"Sane","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0405","first-page":"461A","article-title":"In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters","volume":"52","author":"Huisman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0410","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/lt.23482","article-title":"Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver transplantation","volume":"18","author":"Fontana","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.11.013_b0415","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/ajt.12209","article-title":"Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C","volume":"13","author":"Fontana","year":"2013","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2013.11.013_b0420","first-page":"#LB2","article-title":"Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infection after liver transplantation: Preliminary results of a prospective, multicenter study","volume":"58","author":"Charlton Gane","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0425","first-page":"S416","article-title":"TMC435 and drug interactions: evaluation of the metabolic interactions of TMC435 via cytochrome P450 (CYP) enzymes in health volunteers","volume":"52","author":"Sekar","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0430","first-page":"213A","article-title":"No clinically significant interaction between the investigational HCV protease inhibitor, TMC435 and the immunosuppressives cyclosporine and tacrolimus","volume":"56","author":"Ouwerkerk-Mahadevan","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0435","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jhep.2010.08.040","article-title":"Potency, safety, and pharmacokinetics of the NS3\/4A protease inhibitor BI210335 in patients with chronic HCV genotype 1 infection","volume":"54","author":"Manns","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0440","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1016\/S0168-8278(11)61206-3","article-title":"Pharmacokinetics, safety and tolerability of the HCV NS5A inhibitor ABT-267 following single and multiple doses in healthy adult volunteers","volume":"54","author":"Dumas","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0445","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1016\/S0168-8278(09)60957-0","article-title":"Preclinical potency and ADME characterization of ABT-333, a novel non-nucleoside HCV polymerase inhibitor","volume":"50","author":"Maring","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0450","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hep.23696","article-title":"Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop","volume":"52","author":"Fontana","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0455","first-page":"182","article-title":"Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN Prospective study","volume":"53","author":"Molleston","year":"2011","journal-title":"JPGN"},{"key":"10.1016\/j.jhep.2013.11.013_b0460","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","article-title":"Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States","volume":"137","author":"Ostapowicz","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2013.11.013_b0465","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/hep.23937","article-title":"Drug induced acute liver failure: results of a US multicenter, prospective study","volume":"52","author":"Reuben","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0470","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/gut.44.5.731","article-title":"The natural history of histologically proved drug induced liver disease","volume":"44","author":"Aithal","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2013.11.013_b0475","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jhep.2008.10.021","article-title":"The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice","volume":"50","author":"Bjornsson","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0480","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1365-2036.2006.03117.x","article-title":"Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic","volume":"24","author":"De Valle","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2013.11.013_b0485","first-page":"64","article-title":"The burden of acute non-fulminant drug-induced hepatitis in a United States tertiary referral center","volume":"39","author":"Galan","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2013.11.013_b0490","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of drug-induced hepatic injuries: a french population-based study","volume":"36","author":"Sgro","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0495","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bjornsson","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.11.013_b0500","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, clinical features, and outcomes from a prospective study of drug induced liver injury in the United States","volume":"135","author":"Chalasani","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.11.013_b0505","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.11.013_b0510","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1872-034X.2008.00486.x","article-title":"Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006","volume":"39","author":"Takikawa","year":"2009","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2013.11.013_b0515","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2010.02.008","article-title":"Important elements for the diagnosis of drug induced liver injury","volume":"8","author":"Agarwal","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0520","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/clpt.2012.40","article-title":"The effects of heparins on the liver: application of mechanistic biomarkers in a randomized study in healthy volunteers","volume":"92","author":"Harrill","year":"2012","journal-title":"Clin Pharm Ther"},{"key":"10.1016\/j.jhep.2013.11.013_b0525","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of International Consensus Meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jhep.2013.11.013_b0530","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/hep.23577","article-title":"Comparison between expert opinion and RUCAM for assignment of causality in drug-induced liver injury","volume":"51","author":"Rockey","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0535","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hep.26175","article-title":"LiverTox: a website on drug induced liver injury","volume":"57","author":"Hoofnagle","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0540","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.26208","article-title":"High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury","volume":"58","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0545","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","article-title":"Rationale, design and conduct of the drug induced liver injury network prospective study","volume":"32","author":"Fontana","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.jhep.2013.11.013_b0550","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/jlts.2003.50096","article-title":"Recurrent primary biliary cirrhosis","volume":"9","author":"Neuberger","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.11.013_b0555","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.26756","article-title":"Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults","volume":"34","author":"Heneghan","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0560","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1055\/s-0031-1272834","article-title":"De novo autoimmune hepatitis after liver transplantation","volume":"31","author":"Guido","year":"2011","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2013.11.013_b0565","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1053\/j.gastro.2011.07.051","article-title":"Role of acute hepatitis E in suspected drug-induced liver injury","volume":"141","author":"Davern","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.11.013_b0570","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1053\/j.gastro.2011.02.050","article-title":"Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants","volume":"140","author":"Kamar","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.11.013_b0575","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hep.510310129","article-title":"Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection","volume":"31","author":"Wong","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0580","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2013.11.013_b0585","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1016\/j.transproceed.2007.08.096","article-title":"A clinical-pathological analysis of drug-induced hepatic injury after liver transplantation","volume":"39","author":"Zhenglu","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jhep.2013.11.013_b0590","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/lt.23424","article-title":"Frequency and clinical presentation and outcomes of drug-induced liver injury after liver transplantation","volume":"18","author":"Sembera","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.11.013_b0595","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1016\/j.ijid.2008.12.016","article-title":"Severe and long-lasting cholestasis after high dose co-trimoxazole treatment for pneumocystis pneumonia in HIV-infected patients \u2013 A report of two cases","volume":"13","author":"Hanses","year":"2009","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jhep.2013.11.013_b0600","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1056\/NEJM199709183371204","article-title":"Transfer of symptomatic peanut allergy to the recipient of a combined liver-and-kidney transplant","volume":"337","author":"Legendre","year":"1997","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jhep.2013.11.013_b0605","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00008571-200208000-00003","article-title":"Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine s-methyltransferase polymorphism","volume":"12","author":"Schwab","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jhep.2013.11.013_b0610","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-0676.1991.tb00497.x","article-title":"Reversible cholestasis with bile duct injury following azathioprine therapy. A case report","volume":"11","author":"Horsmans","year":"1991","journal-title":"Liver"},{"key":"10.1016\/j.jhep.2013.11.013_b0615","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/hep.1840140511","article-title":"Azathioprine hepatotoxicity after liver transplantation","volume":"14","author":"Sterneck","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0620","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hep.1840200114","article-title":"Nodular regenerative hyperplasia of the liver graft after liver transplantation","volume":"20","author":"Gane","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.11.013_b0625","first-page":"40","article-title":"Safety of mycophenolate mofetil monotherapy in patients after liver transplantation","volume":"14","author":"Kamphues","year":"2009","journal-title":"Ann Transplant"},{"key":"10.1016\/j.jhep.2013.11.013_b0630","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/03009740600844274","article-title":"Acute hepatitis following mycophenolate mofetil administration for ANCA-positive vasculitis","volume":"36","author":"Dourakis","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0635","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/01.tp.0000231873.86048.68","article-title":"Mycophenolate sodium-induced hepatotoxicity: first report","volume":"82","author":"Loupy","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2013.11.013_b0640","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1272\/jnms.75.187","article-title":"Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation","volume":"75","author":"Taniai","year":"2008","journal-title":"J Nippon Med Sch"},{"key":"10.1016\/j.jhep.2013.11.013_b0645","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/00007890-198112000-00007","article-title":"Cyclosporine a hepatotoxicity in 66 renal allograft recipients","volume":"32","author":"Klintmalm","year":"1981","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2013.11.013_b0650","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.athoracsur.2009.09.081","article-title":"Calcineurin inhibitor-related cholestasis complicating lung transplantation","volume":"89","author":"Oto","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jhep.2013.11.013_b0655","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00007890-198701000-00009","article-title":"Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients","volume":"43","author":"Lorber","year":"1987","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2013.11.013_b0660","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0168-8278(98)80180-3","article-title":"Inhibition of biliary glutathione secretion of cyclosporine a in the rate possible mechanisms and role in the cholestasis induced by the drug","volume":"29","author":"Moran","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.11.013_b0665","first-page":"967","article-title":"Severe sirolimus-induced acute hepatitis in a renal transplant recipient","volume":"23","author":"Jacques","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2013.11.013_b0670","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1345\/aph.1E165","article-title":"Sirolimus-associated hepatotoxicity in liver transplantation","volume":"38","author":"Neff","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jhep.2013.11.013_b0675","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/jlts.2000.19023","article-title":"Experience with the use of sirolimus in liver transplantation \u2013 Use in patients for whom calcineurin inhibitors are contraindicated","volume":"6","author":"Chang","year":"2000","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.11.013_b0680","doi-asserted-by":"crossref","first-page":"128","DOI":"10.12659\/AOT.882646","article-title":"Amoxicillin\/clavulanic acid-induced cholestatic liver injury after pediatric liver transplantation","volume":"17","author":"Studniarz","year":"2012","journal-title":"Ann Transplant"},{"key":"10.1016\/j.jhep.2013.11.013_b0685","first-page":"175","article-title":"Trimethoprim-sulfamethoxasole associated hepatotoxicity \u2013 part of a hypersensitivity syndrome","volume":"10","author":"Mainra","year":"2003","journal-title":"Can J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2013.11.013_b0690","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.trsl.2012.12.012","article-title":"Drug induced severe adverse reaction enhanced by human herpes virus-6 reactivation","volume":"161","author":"Neuman","year":"2013","journal-title":"Transl Res"},{"key":"10.1016\/j.jhep.2013.11.013_b0695","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/516975","article-title":"Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity","volume":"25","author":"Bronstein","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2013.11.013_b0700","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/lt.20690","article-title":"Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis","volume":"12L","author":"Cruciani","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.11.013_b0705","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/lt.22125","article-title":"Acute liver failure due to anti-tubercular therapy: strategy for antitubercular treatment before and after liver transplantation","volume":"16","author":"Ichai","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.11.013_b0710","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/lt.22203","article-title":"Detection and management of latent tuberculosis in liver transplant patients","volume":"17","author":"Jafri","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.11.013_b0715","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1111\/j.1600-6143.2005.01087.x","article-title":"Management of tuberculosis in the transplant recipient","volume":"5","author":"Rubin","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2013.11.013_b0720","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/00003495-200565060-00012","article-title":"Valganciclovir: a review of its use in the management of CMV infectin and disease in immunocompromised patients","volume":"65","author":"Cvetkovic","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.jhep.2013.11.013_b0725","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.yrtph.2011.08.008","article-title":"Herbal hepatotoxicity by greater celandine (Chelidonium majus): Causality assessment of 22 spontaneous reports","volume":"61","author":"Teschke","year":"2011","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.jhep.2013.11.013_b0730","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/lt.22360","article-title":"Energy drinks: another red flag for the liver allograft","volume":"17","author":"Apestegui","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.11.013_b0735","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/TP.0b013e3181daac69","article-title":"Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient","volume":"90","author":"Herden","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2013.11.013_b0740","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1097\/TP.0b013e3182115bc1","article-title":"Acute amiodarone hepatotoxicity after liver transplantation","volume":"91","author":"Von Vital","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2013.11.013_b0745","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.CCM.0000151048.72393.44","article-title":"Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature","volume":"33","author":"Ritz Bravo","year":"2005","journal-title":"Crit Care Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827813008143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827813008143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T22:56:51Z","timestamp":1746053811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827813008143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":149,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0168827813008143"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2013.11.013","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2013.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}